Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.
2.
4.

Efficacy of triple therapy with thymalfasin, peginterferon alpha-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders.

Poo JL, Sánchez Avila F, Kershenobich D, García Samper X, Torress-Ibarra R, Góngora J, Cano C, Parada M, Uribe M.

Ann Hepatol. 2008 Oct-Dec;7(4):369-75.

PMID:
19034238
6.

Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C.

Sandoval-Ramirez JL, Mata-Marín JA, Huerta García G, Gaytán-Martínez JE.

J Infect Dev Ctries. 2015 Mar 15;9(3):267-73. doi: 10.3855/jidc.5284.

7.
8.

Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.

Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, Gutiérrez-Reyes G, Cortina D, Oregel JA, Pérez-Pruna C, Sixtos MS, Cruz-Castellanos S, Soto-Ramírez LE, Rodríguez-Díaz R, Fuentes-Romero L, Gutiérrez-Ruiz MC, Kershenobich D.

Rev Invest Clin. 2003 Mar-Apr;55(2):138-42.

PMID:
12827916
9.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J.

N Engl J Med. 2002 Sep 26;347(13):975-82.

10.

Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.

Rustgi VK, Esposito S, Hamzeh FM, Shiffman ML.

Aliment Pharmacol Ther. 2008 Mar 1;27(5):433-40. Epub 2007 Dec 10.

11.

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group..

N Engl J Med. 2004 Jul 29;351(5):438-50.

12.

Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).

Halfon P, Pérusat S, Bourlière M, Bronowicki JP, Trimoulet P, Benhamou Y, Leroy V, Marcellin P, Foucher J, Penaranda G, Chêne G, Couzigou P; ANRS HC16 GAMMATRI Study Group..

J Med Virol. 2010 Dec;82(12):2027-31. doi: 10.1002/jmv.21909.

PMID:
20981789
13.
14.

Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.

Kuboki M, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

J Gastroenterol Hepatol. 2007 May;22(5):645-52. Erratum in: J Gastroenterol Hepatol. 2007 May;22(5):768.

PMID:
17444850
15.

Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.

Jessner W, Stauber R, Hackl F, Datz C, Watkins-Riedel T, Hofer H, Gangl A, Kessler H, Ferenci P.

J Viral Hepat. 2003 Jan;10(1):37-42.

PMID:
12558910
17.

Thymalfasin for the treatment of chronic hepatitis C infection.

Rustgi VK.

Ann N Y Acad Sci. 2007 Sep;1112:357-67. Epub 2007 Jun 28.

PMID:
17600289
18.

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C; ANRS HCO2 RIBAVIC Study Team..

JAMA. 2004 Dec 15;292(23):2839-48.

PMID:
15598915
19.
20.

Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.

Sherman M, Yoshida EM, Deschenes M, Krajden M, Bain VG, Peltekian K, Anderson F, Kaita K, Simonyi S, Balshaw R, Lee SS; Canadian Pegasys Study Group..

Gut. 2006 Nov;55(11):1631-8. Epub 2006 May 18.

Supplemental Content

Support Center